The 4 Best ASX Healthcare Stocks to Buy as the Sector Trades at Two-Decade Valuation Lows

4 ASX Healthcare Stocks to Buy at Valuation Lows

ASX healthcare stocks have had a brutal run. Five years of underperformance, persistent earnings downgrades, and aggressive rate hikes have pushed the sector to levels many investors have not seen in a generation. According to Wilsons Advisory, ASX 100 healthcare stocks now trade at two-decade lows on a relative price-to-earnings basis, with most major names sitting well below their long-term valuation averages. This is not a sector with broken fundamentals. It is a deeply unloved one. In our experience, that is exactly when the best entry points show up.

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

Why ASX Healthcare Stocks Got This Cheap

The RBA’s rate hiking cycle hit high-PE growth stocks the hardest, and healthcare copped it badly. As interest rates rose, the market slashed the premium it was willing to pay for future earnings, compressing multiples across the board. Persistent earnings downgrades from sector heavyweights made things worse, and sentiment turned sharply negative.

The numbers tell the story. According to Wilsons Advisory data, CSL (ASX: CSL) now trades at a 54% discount to its five-year historic average PE. Cochlear (ASX: COH) is trading at roughly a third below its own historical norm. Wilsons Advisory also expects sector earnings per share to grow at a compound annual rate of 14% over the next three years, which is twice the rate forecast for the broader ASX 200. We believe this is a valuation gap that will not stay open forever.

4 Stocks To Look At: The 3 With the Most Compelling Case

Cochlear (ASX:COH) is the name we find most interesting right now. The stock trades at roughly a 33% discount to its own historical average PE, a multi-year low for one of the highest-quality companies on the ASX with over 60% share of the global cochlear implant market. What makes the timing compelling is that Cochlear is now rolling out the Nucleus Nexa, its most significant product launch in over two decades. This product cycle is expected to drive a genuine earnings inflection over the next two years. At current prices, investors are getting access to that growth at a discount that has rarely existed.

Telix Pharmaceuticals (ASX:TLX) is our second high-conviction name. The stock trades at a substantial discount to broker consensus price targets around A$24, with analysts arguing the market is undervaluing Telix’s diagnostics franchise and assigning very little worth to its pipeline. That pipeline includes a potential blockbuster prostate cancer treatment that has not yet been priced in. Brokers also call out the diagnostics business as far more resilient than the market currently appreciates.

Sonic Healthcare (ASX:SHL) is a solid but more patient story. Management has guided FY26 EBITDA of A$1.87 billion to A$1.95 billion, representing growth of up to 13% from FY25, with AI and digital pathology emerging as real tailwinds. It is cheaper than its own history, but near-term catalysts are less defined compared to Cochlear or Telix.

The One to Approach With More Caution

CSL (ASX: CSL) trades at a forward PE of around 14 times, which is below global peers for the first time in over a decade and close to 15-year lows. The value case looks compelling on paper. However, Wilsons Advisory is currently cautious on CSL due to negative earnings momentum and a demanding second-half contribution required to meet full-year guidance. The opportunity is real, but execution risk is elevated right now. Watch the H2 result closely. If management delivers, the valuation starts to look like a genuine screaming buy.

The Investors’ Takeaway for ASX Healthcare Stocks

The sector is objectively cheap, and the structural story, an ageing population, medical innovation, and steady government funding, has not changed. Our view is that Cochlear and Telix offer the best combination of quality and near-term catalysts at current prices. CSL is worth monitoring closely but requires patience. Do not buy the whole sector indiscriminately. Buy the right names, and let the fundamentals do the work.